Status:

COMPLETED

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Lead Sponsor:

Eli Lilly and Company

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.

Eligibility Criteria

Inclusion

  • Present with type 2 diabetes mellitus
  • Have been taking metformin and/or pioglitazone
  • Have received treatment with basal insulin glargine, injected once a day, for greater than or equal to 90 days
  • Have glycosylated hemoglobin A1c (HbA1c) concentration between greater than or equal to 7.5% and less than or equal to 10.5
  • Have a fasting plasma glucose concentration of less than or equal to 6.7 millimoles per liter \[mmol/L, less than or equal to 121 milligrams per deciliter (mg/dL)\], or greater than 6.7 mmol/L (greater than 121 mg/dL) if the investigator considers that further titration of basal insulin glargine is not possible for safety reasons
  • Not pregnant or breastfeeding

Exclusion

  • Have Type 1 Diabetes
  • Their stable dose of pioglitazone is greater than the maximum dose approved for use in combination with insulin in their country
  • Have a body mass index (BMI) greater than 45 kilograms per square meter (kg/m2).
  • Have a history of scheduled mealtime (prandial) insulin use within 12 weeks of the screening visit and the total duration of the prandial insulin treatment was greater than 2 weeks
  • Have had more than one episode of severe hypoglycaemia within 24 weeks prior to entry into the study
  • Have cardiac disease with a functional status that is Class III or IV
  • Have a history of renal or liver disease
  • Have had a blood transfusion or have a blood disorder

Key Trial Info

Start Date :

April 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2012

Estimated Enrollment :

478 Patients enrolled

Trial Details

Trial ID

NCT01175824

Start Date

April 1 2011

End Date

November 1 2012

Last Update

February 24 2014

Active Locations (18)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (18 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Mar del Plata, Argentina, B7600FZN

2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Ramos Mejía, Argentina, B1704ETD

3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Porto Alegre, Brazil, 90035-170

4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

São Paulo, Brazil, 01244-030